EMA revokes eight class waivers for PIPs to 'encourage' development of drugs for children
This article was originally published in SRA
Executive Summary
The European Medicines Agency has revoked eight class waivers for pediatric investigation plans (PIPs) in a bid to encourage companies to develop more new medicines for use in children. The agency has also confirmed nine class waivers on its current list of class waivers, which means there continues to be no requirement for PIPs for medicines for treating these diseases, and it has updated 15 class waivers on the list1-5.
You may also be interested in...
EMA's Revised Pediatric Class Waiver List Comes Into Effect July 28
Marketing authorization applications for medicines that are no longer subject to a class waiver as per the revised list will need a pediatric investigation plan.
Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges
Biosimilars could face new requirements if RACE for Children Act expands PREA to molecularly targeted cancer drugs approved for adult indications; other stakeholders also worry about general feasibility.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.